Search research articles
Contact Us
Filters
Showing results (51-60 of 331) with videos related to
Page
of 34
Sort By:
JAMA Oncology
|
December 4, 2018
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Zaina P Qureshi, Sumimasa Nagai, Charles L Bennett
Urology
|
January 1, 2018
Editorial Comment
Zaina P Qureshi, Oliver Sartor, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door
Y Tony Yang, Brian Chen, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2014
Reply to W. Read
Sandip M Prasad, Oliver Sartor, Charles L Bennett
Urology
|
July 14, 2012
Editorial comment
Sandip M Prasad, Thomas Keane, Charles L Bennett
Best Practice & Research. Clinical Haematology
|
March 29, 2005
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group
Andrew M Evens, Charles L Bennett, Stefano Luminari
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
September 19, 2018
Offshore Pharmaceutical Trials: Evidence, Economics, and Ethics
Y Tony Yang, Brian Chen, Charles L Bennett
JAMA Oncology
|
June 9, 2017
Biosimilars-Curb Your Enthusiasm
Y Tony Yang, Brian Chen, Charles L Bennett
Expert Opinion on Drug Safety
|
August 24, 2016
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise
Terhi Hermanson, Charles L Bennett, Iain C Macdougall
JAMA
|
October 4, 2017
Challenges to Biosimilar Substitution
Brian Chen, Y Tony Yang, Charles L Bennett
Page
of 34
Search research articles
Search
Showing results (51-60 of 331) with videos related to
Sort By:
Page
of 34
JAMA Oncology
|
December 4, 2018
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Zaina P Qureshi, Sumimasa Nagai, Charles L Bennett
Urology
|
January 1, 2018
Editorial Comment
Zaina P Qureshi, Oliver Sartor, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door
Y Tony Yang, Brian Chen, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2014
Reply to W. Read
Sandip M Prasad, Oliver Sartor, Charles L Bennett
Urology
|
July 14, 2012
Editorial comment
Sandip M Prasad, Thomas Keane, Charles L Bennett
Best Practice & Research. Clinical Haematology
|
March 29, 2005
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group
Andrew M Evens, Charles L Bennett, Stefano Luminari
Mayo Clinic Proceedings. Innovations, Quality & Outcomes
|
September 19, 2018
Offshore Pharmaceutical Trials: Evidence, Economics, and Ethics
Y Tony Yang, Brian Chen, Charles L Bennett
JAMA Oncology
|
June 9, 2017
Biosimilars-Curb Your Enthusiasm
Y Tony Yang, Brian Chen, Charles L Bennett
Expert Opinion on Drug Safety
|
August 24, 2016
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise
Terhi Hermanson, Charles L Bennett, Iain C Macdougall
JAMA
|
October 4, 2017
Challenges to Biosimilar Substitution
Brian Chen, Y Tony Yang, Charles L Bennett
Page
of 34